Protagenic cuts $6.3M debt, cancels merger shares | PTIX Stock News
Share cancellation, over $1M in annual cost cuts and liabilities down from $6.8M to $0.5M leave Protagenic leaner and centered on PT00114 Phase 2 in 2026.
www.stocktitan.netI don’t have live access to current news feeds in this moment. Here’s a concise summary based on the latest publicly available snippets I can reference:
- Protagenic Therapeutics (ticker PTIX) has been in the spotlight for PT00114, its lead peptide program, with recent updates indicating progression toward Phase 2 in 2026 and positive Phase 1 safety data for multiple-dose administration. These milestones have typically influenced investor sentiment and stock volatility in the biotech sector.[1][2]
- Recent restructuring actions in early 2026 aimed at strengthening the balance sheet and refocusing on PT00114, including debt reduction and cost-cutting measures, were reported to have driven a favorable market reaction alongside continued emphasis on advancing the Phase 2 program.[2]
- Broader coverage over the past year has included stock-price movements and periodic news about clinical trial safety readouts, potential phase progression timelines, and investor-focused updates, though coverage depth varies by outlet.[3][4]
If you’d like, I can perform a fresh web search for the latest articles and provide a summarized timeline with links. I can also pull specific details about PT00114 trial design, safety endpoints, and the current Phase 2 expectations, or track recent market reactions in a short table. Please let me know which you prefer.